Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12933479 | 0.94 | TP53 (0.46) | ALDH1A1 | |
| SCHEMBL1064521 | 0.90 | ALDH1A1 (0.44) | DRD4ALDH1A1HDAC1HDAC6 | |
| SCHEMBL1062906 | 0.90 | DRD4 (0.43) | DRD4ALDH1A1LMNAGAASMN1; SMN2 | |
| SCHEMBL1061924 | 0.87 | DRD4 (0.49) | DRD4SMN1; SMN2 | |
| SCHEMBL1062151 | 0.86 | SMO (0.46) | ALDH1A1 | |
| SCHEMBL10314502 | 0.86 | HDAC1 (0.44) | DRD4ALDH1A1HDAC1HDAC11HDAC8 | |
| Hydrochloric Acid SCHEMBL1061359 | 0.85 | HDAC1 (0.43) | DRD4ALDH1A1HDAC1HDAC11HDAC8 | |
| SCHEMBL12933517 | 0.84 | TP53 (0.47) | ALDH1A1LMNAHDAC1HDAC6 | |
| SCHEMBL12933480 | 0.84 | TP53 (0.46) | ALDH1A1 | |
| SCHEMBL1060796 | 0.84 | POLB (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399449-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003788-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | DRD4 1488/4885ALDH1A1 745/4885LMNA 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.